• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study

    Author(s)
    McInnes, Iain B
    Kirkham, Bruce
    Nash, Peter
    Rahman, Proton
    Gottlieb, Alice B
    Ding, Kevin
    Pricop, Luminita
    Griffith University Author(s)
    Nash, Peter
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    Background: Secukinumab (SEC), a fully human monoclonal antibody that selectively neutralises interleukin-17A, provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). Objectives: To report 4-year efficacy and safety results from the FUTURE 2 study. 3-year data is presented here, with 4-year data to follow. Methods: Overall, 397 patients with active PsA were randomised to receive subcutaneous SEC (300, 150 or 75 mg) or placebo (PBO) at baseline (BL), Weeks 1, 2, 3 and 4, and every 4 weeks thereafter. Assessments at week 156 ...
    View more >
    Background: Secukinumab (SEC), a fully human monoclonal antibody that selectively neutralises interleukin-17A, provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). Objectives: To report 4-year efficacy and safety results from the FUTURE 2 study. 3-year data is presented here, with 4-year data to follow. Methods: Overall, 397 patients with active PsA were randomised to receive subcutaneous SEC (300, 150 or 75 mg) or placebo (PBO) at baseline (BL), Weeks 1, 2, 3 and 4, and every 4 weeks thereafter. Assessments at week 156 are from patients originally randomised to SEC and included ACR20/50, PASI 75, HAQ-DI, and resolution of dactylitis and enthesitis. Analyses by prior anti-tumour necrosis factor (TNF) use (naive/inadequate response [IR]) and with/without concomitant methotrexate (MTX) were assessed. Data are reported as observed for SEC 300 and 150 mg (approved doses). Safety analyses included all patients who received ≥1 dose of SEC. Results: In total, 73/100 (73.0%) and 72/100 (72.0%) patients in the SEC 300 and 150 mg groups, respectively, completed 156 weeks of treatment. Sustained clinical improvements were observed in those continuing with SEC across all endpoints through week 156 (Table 1). ACR20 response rates at week 156 in anti-TNF-naive patients were 85.2% and 76.5% with SEC 300 and 150 mg respectively; corresponding rates in anti-TNF-IR patients were 55.6% and 54.5%, respectively. ACR20 response rates in patients receiving concomitant MTX were 73.0% and 77.1% with SEC 300 and 150 mg, respectively; rates in patients without concomitant MTX use were 77.3% and 63.2%, respectively. Over the study (mean SEC exposure of 991.3 days) the type, incidence and severity of adverse events (AEs) were consistent with that reported previously. Exposure adjusted incidence rates with SEC for selected AEs of interest were: serious infections (1.8), Candida infections (1.8), inflammatory bowel disease (0.1), major adverse cardiovascular event (0.2) and malignant/unspecified tumours (1.2). Conclusion: SEC 300 and 150 mg provided sustained improvements in the signs and symptoms of active PsA through 3 years. Secukinumab was well tolerated, with a safety profile consistent with that reported previously.
    View less >
    Conference Title
    Rheumatology
    Volume
    58
    Issue
    Supplement_3
    DOI
    https://doi.org/10.1093/rheumatology/kez107.072
    Subject
    Clinical sciences
    Immunology
    Science & Technology
    Life Sciences & Biomedicine
    Rheumatology
    Publication URI
    http://hdl.handle.net/10072/401733
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander